ARS Pharmaceuticals (SPRY) Other financing activities (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Other financing activities data on file, last reported at $62000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities fell 91.45% year-over-year to $62000.0; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 44.07% YoY), and the FY2025 full-year result was $5.7 million, up 88.36% from the prior year.
• Other financing activities declined to $62000.0 in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $2.9 million in Q2 2023 to a low of $62000.0 in Q1 2026.
• A 5-year average of $1.1 million and a median of $725000.0 in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities surged 894.43% in 2023 and plunged 91.45% in 2026, its largest moves.
• Tracing SPRY's Other financing activities over 5 years: stood at $283000.0 in 2022, then surged by 537.81% to $1.8 million in 2023, then decreased by 15.07% to $1.5 million in 2024, then grew by 16.11% to $1.8 million in 2025, then sank by 96.52% to $62000.0 in 2026.
• Business Quant data shows SPRY's Other financing activities at $62000.0 in Q1 2026, $1.8 million in Q4 2025, and $479000.0 in Q3 2025.